Cargando…

Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside

Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannemann, Juliane, Zummack, Julia, Hillig, Jonas, Böger, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158260/
https://www.ncbi.nlm.nih.gov/pubmed/32313644
http://dx.doi.org/10.1177/2045894020918846
_version_ 1783522502037733376
author Hannemann, Juliane
Zummack, Julia
Hillig, Jonas
Böger, Rainer
author_facet Hannemann, Juliane
Zummack, Julia
Hillig, Jonas
Böger, Rainer
author_sort Hannemann, Juliane
collection PubMed
description Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide is the major vasodilator released from the vascular endothelium. Nitric oxide-dependent vasodilation is impaired in hypoxic conditions. Inhibition of nitric oxide synthesis is the most rapid and easily reversible molecular mechanism to regulate nitric oxide-dependent vascular function in response to physiological and pathophysiological stimuli. Asymmetric dimethylarginine is an endogenous, competitive inhibitor of nitric oxide synthase and a risk marker for major cardiovascular events and mortality. Elevated asymmetric dimethylarginine has been observed in animal models of hypoxia as well as in human cohorts under chronic and chronic intermittent hypoxia at high altitude. In lowlanders, asymmetric dimethylarginine is high in patients with pulmonary hypertension. We have recently shown that high asymmetric dimethylarginine at sea level is a predictor for high-altitude pulmonary hypertension. Asymmetric dimethylarginine is a highly regulated molecule, both by its biosynthesis and metabolism. Methylation of L-arginine by protein arginine methyltransferases was shown to be increased in hypoxia. Furthermore, the metabolism of asymmetric dimethylarginine by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) is decreased in animal models of hypoxia. Whether these changes are caused by transcriptional or posttranslational modifications remains to be elucidated. Current data suggest a major role of asymmetric dimethylarginine in regulating pulmonary arterial nitric oxide production in hypoxia. Further studies are needed to decipher the molecular mechanisms regulating asymmetric dimethylarginine in hypoxia and to understand their clinical significance.
format Online
Article
Text
id pubmed-7158260
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-71582602020-04-20 Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside Hannemann, Juliane Zummack, Julia Hillig, Jonas Böger, Rainer Pulm Circ Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide is the major vasodilator released from the vascular endothelium. Nitric oxide-dependent vasodilation is impaired in hypoxic conditions. Inhibition of nitric oxide synthesis is the most rapid and easily reversible molecular mechanism to regulate nitric oxide-dependent vascular function in response to physiological and pathophysiological stimuli. Asymmetric dimethylarginine is an endogenous, competitive inhibitor of nitric oxide synthase and a risk marker for major cardiovascular events and mortality. Elevated asymmetric dimethylarginine has been observed in animal models of hypoxia as well as in human cohorts under chronic and chronic intermittent hypoxia at high altitude. In lowlanders, asymmetric dimethylarginine is high in patients with pulmonary hypertension. We have recently shown that high asymmetric dimethylarginine at sea level is a predictor for high-altitude pulmonary hypertension. Asymmetric dimethylarginine is a highly regulated molecule, both by its biosynthesis and metabolism. Methylation of L-arginine by protein arginine methyltransferases was shown to be increased in hypoxia. Furthermore, the metabolism of asymmetric dimethylarginine by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) is decreased in animal models of hypoxia. Whether these changes are caused by transcriptional or posttranslational modifications remains to be elucidated. Current data suggest a major role of asymmetric dimethylarginine in regulating pulmonary arterial nitric oxide production in hypoxia. Further studies are needed to decipher the molecular mechanisms regulating asymmetric dimethylarginine in hypoxia and to understand their clinical significance. SAGE Publications 2020-04-14 /pmc/articles/PMC7158260/ /pubmed/32313644 http://dx.doi.org/10.1177/2045894020918846 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung
Hannemann, Juliane
Zummack, Julia
Hillig, Jonas
Böger, Rainer
Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title_full Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title_fullStr Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title_full_unstemmed Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title_short Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
title_sort metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
topic Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158260/
https://www.ncbi.nlm.nih.gov/pubmed/32313644
http://dx.doi.org/10.1177/2045894020918846
work_keys_str_mv AT hannemannjuliane metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside
AT zummackjulia metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside
AT hilligjonas metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside
AT bogerrainer metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside